Gilead price target raised to $110 from $105 at Piper Sandler
Piper Sandler raised the firm’s price target on Gilead (GILD) to $110 from $105 and keeps an Overweight rating on the shares after the company ...
Gilead price target raised to $120 from $105 at Wells Fargo
Wells Fargo analyst Mohit Bansal raised the firm’s price target on Gilead (GILD) to $120 from $105 and keeps an Overweight rating on the ...
Canaccord raises Travere Therapeutics target to $45; Keeps Buy
Canaccord Genuity maintained a Buy rating on Travere Therapeutics (NASDAQ:TVTX) and significantly increased the price target to $45 from the previous $22. The adjustment reflects the firm's continued ...
2025 AI Predictions For Small Businesses
Rieva Lesonsky interviews industry experts to learn how AI is transforming small businesses and their predictions for AI's ...